Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration.

Marta Jóźwiak-Bębenista, Anna Stasiak, Monika Sienkiewicz, Paweł Kwiatkowski, Edward Kowalczyk

Abstract readReview

In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marta Jóźwiak-BębenistaDepartment of Pharmacology and Toxicology, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland.ORCID 0000-0001-9032-1438

Anna StasiakDepartment of Hormone Biochemistry, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland.ORCID 0000-0002-2225-7312

Monika SienkiewiczDepartment of Pharmaceutical Microbiology and Microbiological Diagnostic, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0002-9823-4176

Paweł KwiatkowskiDepartment of Diagnostic Immunology, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland.ORCID 0000-0003-0016-0541

Edward KowalczykDepartment of Pharmacology and Toxicology, Medical University of Lodz, Zeligowskiego 7/9, 90-752 Lodz, Poland.ORCID 0000-0002-2250-6040

Funding

Medical University of Lodz 503/1-108-01/503-11-001

6 · The paper itself

Abstract

Aging is associated with chronic, low-grade inflammation ("inflammaging"), which contributes to neuropsychiatric and neurodegenerative disorders such as depression, Alzheimer's disease, and Parkinson's disease. Conventional pharmacotherapies often provide limited benefit in older adults and are further complicated by polypharmacy and drug-drug interactions. Psilocybin, a serotonergic psychedelic acting primarily as a partial agonist at the 5-HT

Indexed as

AgingDepressionHallucinogensInflammationNeurodegenerative DiseasesPsilocybinAgedAnimalsHumansHallucinogensPsilocybin5-HT2Aageddepressioninflammationneurodegenerative diseasesneuronal plasticitypsilocybinreceptorserotonin

Identifiers

PMID42196212

DOI10.3390/ijms27104229

PMCPMC13207415

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.